GlassScriptPhysician profile
Erynn E Elleby
NPI 1881033710
$6,500.02
in general payments reported to CMS, 2019-2025
30 companies · $2,164 in 2025
The $2,164 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $537 · 2021: $769 · 2022: $420 · 2023: $1,013 · 2024: $1,288 · 2025: $2,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,465.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,920.09 | 2019-2025 | |
| Novo Nordisk INC | $953.01 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $917.07 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $600.57 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $328.71 | 2020-2025 | |
| Amgen INC. | $282.16 | 2019-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.64 | 2020-2025 | Jardiance |
| Abbott Laboratories | $142.83 | 2024-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $138.71 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $125.58 | 2020 | |
| Dexcom, INC. | $122.25 | 2022-2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $117.79 | 2019-2025 | Veozah, Myrbetriq |
| Insulet Corporation | $84.16 | 2025 | Omnipod |
| Biohaven Pharmaceuticals, INC. | $71.06 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $70.48 | 2025 | Caplyta |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $69.48 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $60.44 | 2022 | |
| Axsome Therapeutics, INC. | $58.38 | 2024 | Auvelity |
| Currax Pharmaceuticals LLC | $44.34 | 2023-2025 | Contrave |
| Novartis Pharmaceuticals Corporation | $40.55 | 2024 | |
| Edwards Lifesciences Corporation | $30.51 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Merck Sharp & Dohme LLC | $26.82 | 2019 | |
| Sanofi Pasteur INC. | $23.48 | 2023 | |
| Amarin Pharma, INC. | $22.83 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.14 | 2020 | |
| Itamar Medical INC | $17.89 | 2025 | Watchpatone |
| Sunovion Pharmaceuticals INC. | $15.43 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.83 | 2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $13.44 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erynn Elleby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.